At a glance
- Originator Ebewe; Novartis
- Class Antiasthmatics; Xanthines
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 31 Aug 1998 No-Development-Reported for Asthma (Unknown route)
- 29 Aug 1996 New profile
- 29 Aug 1996 Preclinical development for Asthma (Unknown route)